Preliminarily comparison of multiple radiographic modalities in evaluation of response to treatment of bone metastasis with Ra-223
- Conditions
- CRPC patients with bone metastasis
- Registration Number
- JPRN-UMIN000039051
- Lead Sponsor
- ippon Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Not provided
(1)Prior treatment within 1 week before enrollment or any combination use during the study with abiraterone and prednisone/prednisolone, enzalutamide, or chemotherapies (2)Prior hemibody external radiation (3)Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bone metastases within previous 24 weeks (4)Had history of gastrointestinal bleeding or ulcer within 3 months prior to study entry (5)Other malignancy treated prior to enrollment (except non-melanoma skin cancer or low-grade superficial bladder cancer) (6)History of visceral metastasis, or visceral metastases as assessed by screening imaging examination (7)Known brain metastasis (8)Malignant lymphadenopathy exceeding 3 cm in short-axis diameter (9)Imminent or established spinal cord compression based on clinical findings and/or MRI (Magnetic Resonance Imaging) (10)Any other serious illness or medical condition (11)Substance abuse, medical, psychological, or social conditions that might interfere with the subject's participation in the study or evaluation of the study (12)Those who have any contraindication to MRI or other Magnetic Imaging
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To preliminarily compare multiple modalities (SPECT-CT, FDG-PET and MRI) in terms of predicting overall survival after Ra-223 treatment in CRPC patients with bone metastasis
- Secondary Outcome Measures
Name Time Method To preliminarily compare multiple modalities in terms of predictability of SSE-FS